Urinary system cancer that results in malignant growth located in the urinary bladder.
1
Therefore, common variation in DNA repair genes might modify bladder cancer risk.
2
Therefore, REG1a targeting in bladder cancer patients represents a promising therapeutic strategy.
3
However, the effect of HCS on bladder cancer has not been elucidated.
4
In contrast, physical activity showed no statistically significant relation with bladder cancer.
5
Laparoscopic surgical procedures are being evaluated in urologic diseases including bladder cancer.
6
Arsenic is associated with bladder cancer risk even at low exposure levels.
7
Urocidin, a bladder cancer treatment, is currently undergoing phase III clinical testing.
8
Cytokeratin 20 and survivin were used as confirmed markers of bladder cancer.
9
Patients with advanced bladder cancer frequently receive a chemotherapy regimen containing doxorubicin.
10
Typical median overall survival for metastatic bladder cancer is about 9 months.
11
This study examined the relationship between arsenic exposure and bladder cancer mortality.
12
Ellis died earlier this month after he was diagnosed with bladder cancer.
13
VEGF expression in bladder cancer is associated with REG1a expression and recurrence.
14
He revealed in November that he was being treated for bladder cancer.
15
It is seeking approval of drugs to treat hypogonadism and bladder cancer.
16
REG1a was overexpressed in bladder cancer tissues compared with adjacent normal samples.